Hang Seng Biotech Index Jumps Over 4%, Genscript Biotech Up 11%

The rally's breadth matters more than any single name: a contract-research player, an AI drug-discovery listing and a large-cap pharma all moving together suggests sector-level positioning rather than one company's news. Insilico's move is the notable signal, since AI-driven discovery remains a distinct sub-theme within the broader biotech complex. Whether this is a durable re-rating of Hong Kong-listed biotech or a single-session rotation is the open question, and follow-through in the index over subsequent sessions is what would distinguish the two.